Avrobio Analyst Ratings
Avrobio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2023 | 39.86% | Wells Fargo | $2.5 → $2 | Maintains | Overweight |
| 07/12/2023 | 39.86% | Wedbush | → $2 | Downgrades | Outperform → Neutral |
| 03/24/2023 | 249.65% | Mizuho | $6 → $5 | Maintains | Buy |
| 03/24/2023 | 319.58% | Needham | → $6 | Reiterates | → Buy |
| 12/08/2022 | 179.72% | BTIG | → $4 | Upgrades | Neutral → Buy |
| 05/17/2022 | 319.58% | Needham | $8 → $6 | Maintains | Buy |
| 05/11/2022 | 179.72% | Barclays | $6 → $4 | Maintains | Overweight |
| 01/06/2022 | 319.58% | Mizuho | $28 → $6 | Maintains | Buy |
| 01/05/2022 | 319.58% | Barclays | $22 → $6 | Maintains | Overweight |
| 01/05/2022 | 109.79% | Morgan Stanley | $7 → $3 | Maintains | Equal-Weight |
| 01/05/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 01/05/2022 | 459.44% | Needham | $28 → $8 | Maintains | Buy |
| 11/19/2021 | 389.51% | Morgan Stanley | $24 → $7 | Downgrades | Overweight → Equal-Weight |
| 10/12/2021 | 1648.25% | Morgan Stanley | $27 → $25 | Maintains | Overweight |
| 07/16/2021 | 1927.97% | Morgan Stanley | $31 → $29 | Maintains | Overweight |
| 06/15/2021 | 1508.39% | BTIG | → $23 | Initiates Coverage On | → Buy |
| 05/27/2021 | 1858.04% | Needham | → $28 | Maintains | Buy |
| 05/14/2021 | 2067.83% | Morgan Stanley | $34 → $31 | Maintains | Overweight |
| 05/03/2021 | 599.3% | SVB Leerink | $18 → $10 | Maintains | Market Perform |
| 03/09/2021 | 1508.39% | Barclays | → $23 | Initiates Coverage On | → Overweight |
| 03/02/2021 | 879.02% | Stifel | → $14 | Initiates Coverage On | → Hold |
| 11/11/2020 | 1788.11% | Berenberg | → $27 | Initiates Coverage On | → Buy |
| 10/13/2020 | 2277.62% | Morgan Stanley | $35 → $34 | Maintains | Overweight |
| 07/15/2020 | 2347.55% | Morgan Stanley | $37 → $35 | Maintains | Overweight |
| 03/31/2020 | 2487.41% | Morgan Stanley | $40 → $37 | Maintains | Overweight |
| 03/31/2020 | 809.09% | HC Wainwright & Co. | $35 → $13 | Downgrades | Buy → Neutral |
| 03/31/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 02/12/2020 | 2697.2% | Morgan Stanley | $37 → $40 | Maintains | Overweight |
| 11/11/2019 | 2137.76% | Wedbush | $43 → $32 | Maintains | Outperform |
| 10/28/2019 | 2347.55% | Nomura | → $35 | Initiates Coverage On | → Buy |
| 06/27/2019 | 1858.04% | Mizuho | → $28 | Initiates Coverage On | → Buy |
| 04/05/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 11/28/2018 | 1788.11% | Leerink Swann | → $27 | Initiates Coverage On | → Market Perform |
| 09/17/2018 | 3186.71% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 08/13/2018 | 2697.2% | Morgan Stanley | $37 → $40 | Maintains | Overweight |
| 07/16/2018 | 2697.2% | Wells Fargo | → $40 | Initiates Coverage On | → Outperform |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 2557.34% | Wedbush | → $38 | Initiates Coverage On | → Outperform |
| 07/16/2018 | 2487.41% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/13/2023 | 39.86% | 富国银行 | $2.5→$2 | 维护 | 超重 |
| 07/12/2023 | 39.86% | 韦德布什 | →$2 | 评级下调 | 跑赢→中性 |
| 03/24/2023 | 249.65% | 瑞穗 | $6→$5 | 维护 | 买 |
| 03/24/2023 | 319.58% | 李约瑟 | →$6 | 重申 | →购买 |
| 12/08/2022 | 179.72% | BTIG | →$4 | 升级 | 中性→购买 |
| 2022/05/17 | 319.58% | 李约瑟 | $8→$6 | 维护 | 买 |
| 2022年05月11日 | 179.72% | 巴克莱 | $6→$4 | 维护 | 超重 |
| 01/06/2022 | 319.58% | 瑞穗 | $28→$6 | 维护 | 买 |
| 01/05/2022 | 319.58% | 巴克莱 | $22→$6 | 维护 | 超重 |
| 01/05/2022 | 109.79% | 摩根士丹利 | $7→$3 | 维护 | 等重 |
| 01/05/2022 | - | BTIG | 评级下调 | 购买→中性 | |
| 01/05/2022 | 459.44% | 李约瑟 | $28→$8 | 维护 | 买 |
| 2021年11月19日 | 389.51% | 摩根士丹利 | $24→$7 | 评级下调 | 超重→等重 |
| 10/12/2021 | 1648.25% | 摩根士丹利 | $27→$25 | 维护 | 超重 |
| 07/16/2021 | 1927.97% | 摩根士丹利 | $31→$29 | 维护 | 超重 |
| 2021/06/15 | 1508.39% | BTIG | →$23 | 开始承保 | →购买 |
| 2021/05/27 | 1858.04% | 李约瑟 | →$28 | 维护 | 买 |
| 2021/05/14 | 2067.83% | 摩根士丹利 | $34→$31 | 维护 | 超重 |
| 05/03/2021 | 599.3% | SVB Leerink | $18→$10 | 维护 | 市场表现 |
| 03/09/2021 | 1508.39% | 巴克莱 | →$23 | 开始承保 | →超重 |
| 03/02/2021 | 879.02% | Stifel | →$14 | 开始承保 | →保留 |
| 11/11/2020 | 1788.11% | 贝伦伯格 | →$27 | 开始承保 | →购买 |
| 10/13/2020 | 2277.62% | 摩根士丹利 | $35→$34 | 维护 | 超重 |
| 07/15/2020 | 2347.55% | 摩根士丹利 | $37→$35 | 维护 | 超重 |
| 03/31/2020 | 2487.41% | 摩根士丹利 | $40→$37 | 维护 | 超重 |
| 03/31/2020 | 809.09% | HC Wainwright公司 | $35→$13 | 评级下调 | 购买→中性 |
| 03/31/2020 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 02/12/2020 | 2697.2% | 摩根士丹利 | $37→$40 | 维护 | 超重 |
| 2019年11月11日 | 2137.76% | 韦德布什 | $43→$32 | 维护 | 跑赢大盘 |
| 2019年10月28日 | 2347.55% | 野村 | →$35 | 开始承保 | →购买 |
| 2019年06月27日 | 1858.04% | 瑞穗 | →$28 | 开始承保 | →购买 |
| 2019年05月04日 | - | 詹尼·蒙哥马利·斯科特 | 开始承保 | →购买 | |
| 2018年11月28日 | 1788.11% | 利林克·斯旺 | →$27 | 开始承保 | →市场表现 |
| 2018年09月17日 | 3186.71% | HC Wainwright公司 | →$47 | 开始承保 | →购买 |
| 2018年08月13日 | 2697.2% | 摩根士丹利 | $37→$40 | 维护 | 超重 |
| 2018年07月16日 | 2697.2% | 富国银行 | →$40 | 开始承保 | →跑赢大盘 |
| 2018年07月16日 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 2018年07月16日 | 2557.34% | 韦德布什 | →$38 | 开始承保 | →跑赢大盘 |
| 2018年07月16日 | 2487.41% | 摩根士丹利 | →$37 | 开始承保 | →超重 |
What is the target price for Avrobio (AVRO)?
Avrobio(Avro)的目标价是多少？
The latest price target for Avrobio (NASDAQ: AVRO) was reported by Wells Fargo on July 13, 2023. The analyst firm set a price target for $2.00 expecting AVRO to rise to within 12 months (a possible 39.86% upside). 5 analyst firms have reported ratings in the last year.
富国银行于2023年7月13日报道了Avrobio(纳斯达克：AVRO)的最新目标价。这家分析公司将目标价定为2.00美元，预计Avro将在12个月内上涨(可能上涨39.86%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Avrobio (AVRO)?
Avrobio(Avro)的最新分析师评级是多少？
The latest analyst rating for Avrobio (NASDAQ: AVRO) was provided by Wells Fargo, and Avrobio maintained their overweight rating.
富国银行对Avrobio(纳斯达克代码：AVRO)的最新分析师评级维持其增持评级。
When is the next analyst rating going to be posted or updated for Avrobio (AVRO)?
Avrobio(Avro)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avrobio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avrobio was filed on July 13, 2023 so you should expect the next rating to be made available sometime around July 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Avrobio的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Avrobio的上一次评级是在2023年7月13日提交的，所以你应该预计下一次评级将在2024年7月13日左右的某个时候公布。
Is the Analyst Rating Avrobio (AVRO) correct?
分析师对Avrobio(Avro)的评级正确吗？
While ratings are subjective and will change, the latest Avrobio (AVRO) rating was a maintained with a price target of $2.50 to $2.00. The current price Avrobio (AVRO) is trading at is $1.43, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但Avrobio(Avro)的最新评级保持不变，目标价在2.50美元至2.00美元之间。Avrobio(Avro)目前的交易价格为1.43美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。